Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
PALOMA
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
- NCT04606381 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on PALOMA (advanced solid malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PALOMA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 31 YouTube videos | |
| 26 posts on X | |
| 24 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Neoplasms
- Interventions
- Ami-LC-MD; Ami-LC; Ami-HC; Ami-HC-CF
- Arms
- Part 1: Ami-LC-MD and Ami-LC · Experimental
- Part 2: Ami-HC and Ami-HC-CF · Experimental
- Enrollment
- 158
- Primary outcomes
- Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
- Number of Participants with Adverse Event (AE)
- Number of Participants with Dose Limiting Toxicity (DLT)
- Number of Participants with Clinical Laboratory Abnormalities
- Sponsor
- Janssen Research & Development, LLC
- Start
- Nov 10, 2020
- Primary completion
- Jul 11, 2024
- Results posted
- No
- Registry record
- NCT04606381 · updated Nov 3, 2026